Suggestions
Sergey Larionov
Board of Advisors. Strategic Partnerships – IceRock MAG Inc. Co-Founder RAM-DB, REALTYX.
Sergey Larionov
Sergey Larionov is a technology entrepreneur and advisor. Some key details about him:
- He is the Co-Founder of REALTYX and RAM-DB1
- He serves as a Board of Advisors for Strategic Partnerships at IceRock MAG Inc.134
- He is highly experienced in building in-memory databases from scratch
- His LinkedIn profile URL is linkedin.com/in/sergey-larionov-85a2266b1
- He is based in Tel Aviv, Israel2
Larionov has over 15 years of experience in the technology industry, with expertise in areas like in-memory databases, real estate tech, and blockchain. He has founded several successful startups and serves as an advisor to help guide the strategic partnerships and growth of IceRock MAG Inc., a blockchain platform for real estate investment.
Highlights
PLOS Pathogens, 2010. (One of the co-authors - Ralph S. Baric). ".... In this study we demonstrate that the combination of Zn2+ and PT at low concentrations (2 mM Zn2+ and 2 mM PT) inhibits the replication of SARS-coronavirus (SARS-CoV) and equine arteritis virus (EAV) in cell culture.
The RNA synthesis of these two distantly related nidoviruses is catalyzed by an RNA-dependent RNA polymerase (RdRp), which is the core enzyme of their multiprotein replication and transcription complex (RTC). Using an activity assay for RTCs isolated from cells infected with SARS-CoV or EAV—thus eliminating the need for PT to transport Zn2+ across the plasma membrane—we show that Zn2+ efficiently inhibits the RNA-synthesizing activity of the RTCs of both viruses.
Enzymatic studies using recombinant RdRps (SARS-CoV nsp12 and EAV nsp9) purified from E. coli subsequently revealed that Zn2+ directly inhibited the in vitro activity of both nidovirus polymerases. More specifically, Zn2+ was found to block the initiation step of EAV RNA synthesis, whereas in the case of the SARS-CoV RdRp elongation was inhibited and template binding reduced.
By chelating Zn2+ with MgEDTA, the inhibitory effect of the divalent cation could be reversed, which provides a novel experimental tool for in vitro studies of the molecular details of nidovirus replication and transcription."
" In current study, we performed an integrative approach to predict antigenic sites in SARS-CoV-2 spike receptor binding domain and found nine potential antigenic sites. The predicted antigenic sites were then assessed for possible molecular similarity with other known antigens in different organisms. Out of nine sites, seven sites showed molecular similarity with 54 antigenic determinants found in twelve pathogenic bacterial species (Mycobacterium tuberculosis, Mycobacterium leprae, Bacillus anthracis, Borrelia burgdorferi, Clostridium perfringens, Clostridium tetani, Helicobacter Pylori, Listeria monocytogenes, Staphylococcus aureus, Streptococcus pyogenes, Vibrio cholera and Yersinia pestis), two malarial parasites (Plasmodium falciparum and Plasmodium knowlesi) and influenza virus A. Most of the bacterial antigens that displayed molecular similarity with antigenic sites in SARS-CoV-2 RBD (receptor binding domain) were toxins and virulent factors."
"Besides this, anti-leprosy, anti-lyme, anti-plague, anti-anthrax drugs/vaccine etc. are also expected to be beneficial in COVID-19 treatment. Moreover, individuals previously immunized/vaccinated or had previous history of malaria, tuberculosis or other disease caused by fifteen microorganisms are expected to display a considerable degree of resistance against SARS-CoV-2 infection."
https://lnkd.in/ggHJSPxC
